Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out
Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and Zepbound maker Eli Lilly a lift.
Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and Zepbound maker Eli Lilly a lift.
